RecruitingNot ApplicableNCT06609941

Additive Effects of Alternative Nostril Breathing with Pharmacological Management on Dyspnea and Control Pause in Patients with Bronchial Asthma

Sponsor

Foundation University Islamabad

Enrollment

32 participants

Start Date

Jun 18, 2024

Study Type

INTERVENTIONAL

Conditions

Bronchial Asthma

Summary

Bronchial asthma is a widespread chronic condition charactrized by inflammation and narrowing of airways, leading to repeateted episodes of breathlessness, wheezing and labored breathing.Breathing exercises help to manage hyperventilation often seen in asthmatic patients. To handle respiratory complications asthmatics are advised to practise nasal breathing techniques in conjunction with their prescribed medications.

Eligibility

Min Age: 18 YearsMax Age: 45 Years

Inclusion Criteria4

Adults: aged (18-45 years)
Gender: Both males and females
Grade1- Grade 4 on Modified MRC dyspnea scale
Asthma severity classes (intermediate, mild persistent and moderate persistent asthma) acc. to NAEPP national asthma education and prevention program guidlin

Exclusion Criteria5

Patients having acute exacerbation of COPD or status asthmaticus
Patients diagnosed with acute infections
Patients unable to follow command/ instructions
Asthma patients with \>40 sec control pause duration
Patients who fall in red zone of asthma action plan (PEFR \< 50%)

Interventions

OTHERAlternative nostril breathing

Patients in this group will receive alternative nostril breathing along with pharmacological management. For alternative nostirl breathing patient will be advised to inhale slowly (4sec) and deeply through left nostril.Then hold breath for 2-3 sec. Release right nostril and use right ring finger to close left nostril. Exhale slowly (6sec) and completely through right nostril. Inhale slowly (4sec) and deeply through right nostril. Then hold breath for 2-3sec. Release left nostril and use right thumb to close right nostril. Exhale slowly (6sec) and completely through left nostril. Repeat the cycle.

DRUGPharmacological therapy

Participants in this group will only be provided with standard pharmacological management for 4 weeks as prescribed by a pulmonologist. For example: Salbutamol inhaler (Short acting bronchodilator) Saltra inhaler (Selective long acting β2 adrenoceptor agonist) Tiotropium (Anticholinergic) Combivir (Nucleoside analogue - reverse transcriptase inhibitor) etc. Week 01 and week 02: Patients will receive medication prescribed by pulmonologist. Week 03 and week 04: Patients will receive medication prescribed by pulmonologist.